| 1. |
- Cederholm, Jan, et al.
(author)
-
Blood pressure and risk of cardiovascular diseases in type 2 diabetes : further findings from the Swedish National Diabetes Register (NDR-BP II)
- 2012
-
In: Journal of Hypertension. - 0263-6352 .- 1473-5598. ; 30:10, s. 2020-2030
-
Journal article (peer-reviewed)abstract
- Objectives: Estimate risks of coronary heart disease (CHD), stroke and cardiovascular disease (CVD) with updated mean systolic (SBP) and diastolic (DBP) blood pressure in an observational study of patients with type 2 diabetes. Methods: Thirty-five thousand and forty-one patients treated with antihypertensive drugs, and 18 512 untreated patients, aged 30-75 years, without previous heart failure, followed for 6 years until 2009. Results: In treated patients, nonlinear splines for 6-year risk of fatal/nonfatal CHD, stroke and CVD by BP as a continuous variable showed a progressive increase with higher SBP from 140 mmHg and higher, and with DBP from 80 mmHg, with a J-shaped risk curve at lowest SBP levels, but not obviously at lowest DBP levels. Analysing intervals of SBP with 130-134 mmHg as reference at Cox regression, adjusted hazard ratios (HR) for fatal/nonfatal CHD, stroke and CVD with at least 140 mmHg were 1.22 [95% confidence interval (CI): 1.08-1.39], 1,43 (1.18-1.72), 1.26 (1.13-1.41), all P<0.001. HR with 115-129 and 135-139 mmHg were nonsignificant, whereas increased with 100-114 mmHg, 1.96 (P<0.001), 1.75 (P=0.02), 2.08 (P < 0.001), respectively. With DBP 75-79 mmHg as reference, adjusted HR for fatal/nonfatal CHD, stroke and CVD with DBP 80-84 mmHg were 1.42 (1.26-1.59), 1.46 (1.24-1.72), 1.39 (1.26-1.53), all P< 0.001. Corresponding HR with DBP at least 85 mmHg were 1.70 (1.50-1.92), 2.35 (1.99-2.77), 1..87 (1.69-2.07), all P < 0.001. Corresponding HR with DBP 60-69 and 70-74 mmHg were nonsignificant. The picture was similar in 7059 patients with previous CVD and in untreated patients. Conclusion: BP around 130-135/75-79 mmHg showed lower risks of cardiovascular diseases in patients with type 2 diabetes.
|
|
| 2. |
- Christiansen, Sara Nysom, et al.
(author)
-
Patient-reported outcomes in axial spondyloarthritis and psoriatic arthritis patients treated with secukinumab for 24 months in daily clinical practice
- 2024
-
In: Seminars in Arthritis and Rheumatism. - 0049-0172 .- 1532-866X. ; 65
-
Journal article (peer-reviewed)abstract
- Objectives: In patients with axial spondyloarthritis (axSpA) or psoriatic arthritis (PsA) initiating secukinumab, we aimed to assess and compare the proportion of patients achieving 6-, 12- and 24-month patient-reported outcomes (PRO) remission and the 24-month retention rates. Patients and methods: Patients with axSpA or PsA from 16 European registries, who initiated secukinumab in routine care were included. PRO remission rates were defined as pain, fatigue, Patient Global Assessment (PGA) ≤2 (Numeric Rating Scale (NRS) 0–10) and Health Assessment Questionnaire (HAQ) ≤0.5, for both axSpA and PsA, and were calculated as crude values and adjusted for drug adherence (LUNDEX). Comparisons of axSpA and PsA remission rates were performed using logistic regression analyses (unadjusted and adjusted for multiple confounders). Kaplan-Meier plots with log-rank test and Cox regression analyses were conducted to assess and compare secukinumab retention rates. Results: We included 3087 axSpA and 3246 PsA patients initiating secukinumab. Crude pain, fatigue, PGA and HAQ remission rates were higher in axSpA than in PsA patients, whereas LUNDEX-adjusted remission rates were similar. No differences were found between the patient groups after adjustment for confounders. The 24-month retention rates were similar in axSpA vs. PsA in fully adjusted analyses (HR [95 %CI] = 0.92 [0.84–1.02]). Conclusion: In this large European real-world study of axSpA and PsA patients treated with secukinumab, we demonstrate for the first time a comparable effectiveness in PRO remission and treatment retention rates between these two conditions when adjusted for confounders.
|
|
| 3. |
- Ghazaei Ardakani, M. Mahdi, et al.
(author)
-
Model Predictive Control for Real-Time Point-to-Point Trajectory Generation
- 2019
-
In: IEEE Transactions on Automation Science and Engineering. - 1545-5955. ; 16:2, s. 972-983
-
Journal article (peer-reviewed)abstract
- The problem of planning a trajectory for robots starting in an initial state and reaching a final state in a desired interval of time is tackled. We propose an approach based on model predictive control to solve the problem of point-to-point trajectory generation for a given final time. We discuss various choices of models, objective functions, and constraints for generating trajectories to transfer the state of the robot, while respecting physical limitations on the motion as well as fulfilling computational real-time requirements. Extensive simulation results illustrate the use of the approach, and experiments on an industrial robot in a challenging ball-catching task show the effectiveness of the approach also in demanding scenarios with real-time constraints on the computation.
|
|
| 4. |
- Guldevall, Karolin, 1981-, et al.
(author)
-
Microchip screening platform for assessment of cytotoxic effector cells
-
Other publication (other academic/artistic)abstract
- Here we report a screening platform for assessment of the cytotoxic potential of individual natural killer (NK) or T cells within larger populations. Human primary NK cells or human Epstein-Barr virus (EBV)- specific T cells were distributed across a silicon-glass microchip containing 32 400 individual microwells loaded with target cells. Through fluorescence screening and automated image analysis the numbers of effector and live or dead target cells in each well could be assessed at different time-points after initial mixing. Cytotoxicity was also studied by time-lapse live-cell imaging in microwells quantifying the killing potential of individual NK cells. Although most resting NK cells (≈75%) were non-cytotoxic to the leukemia cell line K562, some NK cells were able to kill several (≥3) target cells within the 12 hours long experiment. We demonstrate that this assay can be used to enumerate and characterize cytotoxic cells, something that could find clinical applications, e.g. in the selection of donors for stem cell transplantation or generation of highly specific and cytotoxic cells for adoptive immunotherapy.
|
|
| 5. |
- Lindberg, Sara, et al.
(author)
-
Expanded HILUS Trial: A Pooled Analysis of Risk Factors for Toxicity From Stereotactic Body Radiation Therapy of Central and Ultracentral Lung Tumors
- 2023
-
In: INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS. - 0360-3016 .- 1879-355X. ; 117:5, s. 1222-1231
-
Journal article (peer-reviewed)abstract
- Purpose: Stereotactic body radiation therapy for tumors near the central airways implies high-grade toxic effects, as concluded from the HILUS trial. However, the small sample size and relatively few events limited the statistical power of the study. We therefore pooled data from the prospective HILUS trial with retrospective data from patients in the Nordic countries treated outside the prospective study to evaluate toxicity and risk factors for high-grade toxic effects. Methods and Materials: All patients were treated with 56 Gy in 8 fractions. Tumors within 2 cm of the trachea, the mainstem bronchi, the intermediate bronchus, or the lobar bronchi were included. The primary endpoint was toxicity, and the secondary endpoints were local control and overall survival. Clinical and dosimetric risk factors were analyzed for treatment-related fatal toxicity in univariable and multivariable Cox regression analyses.Results: Of 230 patients evaluated, grade 5 toxicity developed in 30 patients (13%), of whom 20 patients had fatal bronchopul-monary bleeding. The multivariable analysis revealed tumor compression of the tracheobronchial tree and maximum dose to the mainstem or intermediate bronchus as significant risk factors for grade 5 bleeding and grade 5 toxicity. The 3-year local control and overall survival rates were 84% (95% CI, 80%-90%) and 40% (95% CI, 34%-47%), respectively.Conclusions: Tumor compression of the tracheobronchial tree and high maximum dose to the mainstem or intermediate bronchus increase the risk of fatal toxicity after stereotactic body radiation therapy in 8 fractions for central lung tumors. Simi-lar dose constraints should be applied to the intermediate bronchus as to the mainstem bronchi.
|
|
| 6. |
|
|
| 7. |
|
|
| 8. |
|
|
| 9. |
- Olofsson, Bjorn, et al.
(author)
-
Path-tracking velocity control for robot manipulators with actuator constraints
- 2017
-
In: Mechatronics (Oxford). - : PERGAMON-ELSEVIER SCIENCE LTD. - 0957-4158 .- 1873-4006. ; 45, s. 82-99
-
Journal article (peer-reviewed)abstract
- An algorithm for high-performance path tracking for robot manipulators in the presence of model uncertainties and actuator constraints is presented. The path to be tracked is assumed given, and the nominal trajectories are computed using, for example, well-known algorithms for time-optimal path tracking. For online path tracking, the nominal, feedforward trajectories are combined with feedback in a control architecture with a secondary controller, such that robustness to uncertainties in model or environment is achieved. The control law is based on existing path-velocity control (PVC), or so called online time scaling, but in addition to speed adaptation along the tangent of the path, the algorithm also comprises an explicit formulation and approach, with several attractive properties, for handling the deviations along the transversal directions of the path. For achieving fast convergence along the normal and binormal directions of the path in 3D motion, the strategy proposed has inherent exponential convergence properties. The result is a complete architecture for path-tracking velocity control (PTVC). The method is evaluated in extensive simulations with manipulators of different complexity, and PTVC exhibits superior performance compared to PVC. (C) 2017 Elsevier Ltd. All rights reserved.
|
|
| 10. |
- Olofsson, Bjorn, et al.
(author)
-
Temperature Stabilization of the Phase-Reference Line at the European Spallation Source
- 2018
-
In: 2018 IEEE Conference on Control Technology and Applications, CCTA 2018. - 9781538676981 ; , s. 1369-1376
-
Conference paper (peer-reviewed)abstract
- We consider temperature stabilization of the phase-reference line at the European Spallation Source, a facility for neutron spallation currently under construction. Based on extensive modeling of the heat dynamics, a prototype model-based control system with associated hardware architecture is developed and experimentally evaluated on a small-scale setup. The results indicate that temperature stability within ±0.1°C is possible to achieve, also with significant disturbances in the ambient temperature expected during operation.
|
|
